Provided by Tiger Trade Technology Pte. Ltd.

Vanguard Health Care ETF

310.88
-4.4300-1.40%
Volume:268.07K
Turnover:83.13M
Market Cap:18.80B
PE:33.75
High:314.43
Open:313.89
Low:308.53
Close:315.31
52wk High:330.75
52wk Low:263.00
Shares:60.49M
Float Shares:60.49M
Volume Ratio:2.18
T/O Rate:0.44%
Dividend:4.60
Dividend Rate:1.48%
EPS(TTM):9.21
EPS(LYR):41.51
ROE:3.75%
ROA:0.89%
PB:0.95
PE(LYR):7.49

Loading ...

General Medicine - Series B Financing Led by Andreessen Horowitz (a16z), with Participation from Matrix, Vxi Capital, Eli Lilly and Company

THOMSON REUTERS
·
Oct 06

Madrigal Announces Publication in the Journal of Hepatology Demonstrating Consistent Rezdiffra Efficacy Across Common MASH Genetic Risk Variants

GlobeNewswire
·
Oct 06

European Shares Gain as Genmab Jumps, Bond Yields Retreat

Reuters
·
Oct 06

LIVE Markets-a Health Boost for the STOXX

Reuters
·
Oct 06

Genmab at 3-Year High After Blood Cancer Drug Combination Study Results

Reuters
·
Oct 06

JPMorgan Unfazed by Rising Rates Impact on China Healthcare, Remains Bullish on Biotech and CXO

Stock News
·
Oct 06

Trump: Thanks Howard Kessler for senior healthcare innovation

Trump's Truth Social latest posts
·
Oct 06

Tech Coast Angels Reports Profitable Atraverse Medical Exit After Johnson & Johnson Acquisition, Citing 70%+ IRR

Reuters
·
Oct 06

BCAL Diagnostics Evolves Into National Early Cancer Detection Platform

TIPRANKS
·
Oct 06

Odyssey Health Extends Promissory Note Maturities to 2027

TIPRANKS
·
Oct 06

L'Oreal Explores Unloading Chemical-Related Liabilities, WSJ Reports

Reuters
·
Oct 06

Medtronic PLC Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Oct 06

AbbVie Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Oct 06

AbbVie Cuts Q3 Adjusted Diluted EPS Outlook to $3.73-$3.77 After $216 Million Acquired Ipr&d, Milestones Expense

Reuters
·
Oct 06

Abbvie - Full-Year 2026 Adj Diluted EPS Guidance Range Including Bought Ipr&D is $13.76-$13.96 - SEC Filing

THOMSON REUTERS
·
Oct 06

Abbvie - Q3 2026 Gaap and Adj Earnings Include $216 Mln Bought Ipr&D and Milestones Expense - SEC Filing

THOMSON REUTERS
·
Oct 06

Abbvie Inc. Fy2026 Shr View $14.02

THOMSON REUTERS
·
Oct 06

Abbvie - Q3 2026 Adj Diluted EPS Guidance Range Including Bought Ipr&D is $3.73-$3.77 - SEC Filing

THOMSON REUTERS
·
Oct 06

Genmab, AbbVie Say New Drug Combo Helps Lymphoma Patients Stay Cancer-Free Longer

MT Newswires Live
·
Oct 06

Genmab and AbbVie Report Landmark Phase 3 Win for Epcoritamab Combo in Frontline DLBCL

TIPRANKS
·
Oct 06